Published in Surgery Litigation and Law Weekly, July 20th, 2007
Ondansetron hydrochloride tablets, the generic equivalent of GlaxoSmithkline's Zofran(R) tablets, will be available in 4 mg and 8 mg strengths. Ondansetron hydrochloride tablets are indicated for prevention of nausea and vomiting caused by cancer chemotherapy, radiation therapy and surgery.
Annual sales of Ondansetron hydrochloride tablets in the US were approximately US$746 million for the twelve months ending March 2007 according to IMS...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly